专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5615670A Powder inhaler with centrifugal force used to meter powder 失效
标题翻译：具有离心力的粉末吸入器用于测量粉末
公开(公告)号：US5615670A
公开(公告)日：1997-04-01
申请号：US468766
申请日：1995-06-06
申请人： Ian Rhodes
发明人： Ian Rhodes
IPC分类号： A61M15/00 , A61M16/00 , B05D7/14 , B65D83/06
CPC分类号： A61M15/0065 , A61M2202/064
摘要： A device for the administration by inhalation of a medicament in dry powder form comprises a medicament reservoir (9) and a medicament metering system (10) including a metering chamber (23) communicable with the reservoir (9), characterized in that the reservoir (9) is mounted in a housing (1) for rotation about an axis and the metering chamber (23) is located radially of the axis, the arrangement being such that the metering chamber (23) is charged with medicament during a charging rotation of the reservoir (9) about the axis.
摘要翻译：用于通过吸入干粉形式的药物来施用的装置包括药物储存器（9）和药物计量系统（10），其包括可与储存器（9）连通的计量室（23），其特征在于储存器 9）安装在用于围绕轴线旋转的壳体（1）中，并且计量腔室（23）位于轴线的径向处，该布置使得在计量腔室（23）的充气旋转期间向计量腔室（23）储存器（9）围绕轴线。

2. 发明授权

US5561292A Mass spectrometer and electron impact ion source thereof 失效
标题翻译：质谱仪及其电子碰撞离子源
公开(公告)号：US5561292A
公开(公告)日：1996-10-01
申请号：US441248
申请日：1995-05-15
申请人： Mark E. Buckley , Ian Koch , Andrew Stevenson
发明人： Mark E. Buckley , Ian Koch , Andrew Stevenson
IPC分类号： H01J49/14 , H01J27/20
CPC分类号： H01J49/14
摘要： An enclosed ion source for generating substantially monoenergetic ions from a gaseous sample comprises a chamber into which the gaseous sample is introduced and which is substantially enclosed by a source block having two electron entrance apertures formed in it and by a source plate having one ion extraction aperture formed in it. Two filaments are disposed outside the chamber and adjacent the electron entrance apertures. The electron impact ion source is characterized by the provision of an electrically conductive shield which is disposed within the chamber and which defines an equipotential region. The electrons, generated from a heated filament, pass into the chamber through one of the electron entrance apertures. The shield allows the passage of molecules of the gaseous sample and the electrons into the equipotential region, so that electron impact ionization of at least some of the sample occurs in the equipotential region. The electron impact source may be incorporated into a conventional mass spectrometer.
摘要翻译：用于从气态样品产生基本上单能离子的封闭离子源包括气体样品被引入其中的腔室，其中基本上由其中形成有两个电子入口孔的源块和由具有一个离子提取孔形成了它。两个细丝设置在室外并且邻近电子入口孔。电子冲击离子源的特征在于提供一种导电屏蔽，其设置在室内并且限定等电位区域。从加热的细丝产生的电子通过电子入口孔之一进入腔室。屏蔽允许气体样品和电子的分子通过等电位区域，使得至少一些样品的电子碰撞电离发生在等电位区域中。电子冲击源可以并入传统的质谱仪中。

3. 发明授权

US5475023A Aqueous pharmaceutical formulations of sodium cromoglycate 失效
标题翻译：色甘酸钠的水性药物制剂
公开(公告)号：US5475023A
公开(公告)日：1995-12-12
申请号：US281792
申请日：1994-07-28
申请人： Lewis J. Baskeyfield , Graham F. Jay , Steven P. Probert
发明人： Lewis J. Baskeyfield , Graham F. Jay , Steven P. Probert
IPC分类号： A61K9/08 , A61K9/00 , A61K31/35 , A61K31/352 , A61K47/10 , A61K47/30 , A61P27/02 , A61K31/045 , A61K47/00
CPC分类号： A61K31/35 , A61K9/0048
摘要： A pharmaceutical formulation comprising a substantially clear aqueous solution having a viscosity of less than 10 mPa.s containing 3.5 to 5% w/v of 1,3-bis(2-carboxychromon-5-yloxy)-propan-2-ol, or a pharmaceutically acceptable salt thereof, as active ingredient and glycerol, the concentration of ions of metals of groups IIA, IB, IIB and IVB of the periodic table or of transition metals being less than 20 ppm.
摘要翻译：一种药物制剂，其包含基本上透明的水溶液，其粘度小于10mPa.s，其含有3.5-5％w / v的1,3-双（2-羧基色酮-5-基氧基） - 丙-2-醇，或其药学上可接受的盐作为活性成分和甘油，周期表IIA，IB，IIB和IVB族金属的离子浓度或过渡金属的浓度小于20ppm。

4. 发明授权

US5428044A Anti-inflammatory 4-aminophenyl derivatives 失效
标题翻译：抗炎4-氨基苯基衍生物
公开(公告)号：US5428044A
公开(公告)日：1995-06-27
申请号：US138375
申请日：1993-10-15
申请人： John R. Bantick , David N. Hardern , Richard A. Appleton , John Dixon , David J. Wilkinson
发明人： John R. Bantick , David N. Hardern , Richard A. Appleton , John Dixon , David J. Wilkinson
IPC分类号： A61K31/35 , A61K31/15 , A61K31/352 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/403 , A61K31/41 , A61K31/415 , A61K31/4184 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/433 , A61K31/44 , A61K31/4427 , A61K31/455 , A61K31/465 , A61K31/47 , A61K31/495 , A61K31/496 , A61K31/50 , A61K31/505 , A61K31/53 , A61P29/00 , A61P43/00 , C07D209/60 , C07D213/82 , C07D215/38 , C07D231/06 , C07D231/38 , C07D233/88 , C07D235/30 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D241/28 , C07D249/04 , C07D249/08 , C07D249/14 , C07D251/02 , C07D253/06 , C07D253/07 , C07D261/14 , C07D263/48 , C07D285/08 , C07D285/12 , C07D285/135 , C07D311/92 , C07D333/36 , C07D333/40 , C07D401/08 , C07D401/10 , C07D401/12 , C07D521/00 , A61K31/535 , A01N43/56
CPC分类号： C07D213/82 , C07D215/38 , C07D231/06 , C07D231/12 , C07D231/38 , C07D233/56 , C07D233/88 , C07D235/30 , C07D237/20 , C07D237/22 , C07D239/42 , C07D239/48 , C07D241/20 , C07D249/04 , C07D249/08 , C07D249/14 , C07D253/07 , C07D261/14 , C07D263/48 , C07D285/08 , C07D285/135 , C07D311/92 , C07D333/36 , C07D401/12
摘要： There are disclosed compounds of the formula (I): ##STR1## in which the variables R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and X are defined in the specification. The compounds are useful as pharmaceuticals, especially as anti-inflammatory agents.
摘要翻译：公开了式（I）化合物：其中变量R1，R2，R3，R4，R5，R6和X在本说明书中定义。这些化合物可用作药物，特别是作为抗炎剂。

5. 发明授权

US5406608A X-ray analysis apparatus 失效
标题翻译： X射线分析仪
公开(公告)号：US5406608A
公开(公告)日：1995-04-11
申请号：US150440
申请日：1993-11-10
申请人： Ravisekhar Yellepeddi , Alexandre Bapst , Pierre-Yves Negro
发明人： Ravisekhar Yellepeddi , Alexandre Bapst , Pierre-Yves Negro
IPC分类号： G01N23/207 , G01N23/22 , G01N23/223
CPC分类号： G01N23/2206 , G01N2223/056 , G01N2223/076 , G01N2223/1016
摘要： A device for performing both elemental and structural analysis of a crystalline sample, comprising a polychromatic x-ray source (11); a mounting means (15) for mounting the sample so that it is illuminated with x-rays; one or more fluorescence channels (17), able to select x-rays of a particular wavelength and energy and having means (20) for detecting said selected x-ray; a diffraction channel (28) able to select a characteristic x-ray wavelength at said source (11) following diffraction of the x-rays by said sample (14) and having means (33) for detecting a selected characteristic x-ray; and an actuating means (32) for controlling arcuate movement of said diffraction channel (28) relative to said sample (14) so as to detect x-rays leaving the sample at different diffraction angles.
摘要翻译：一种用于执行结晶样品的元素和结构分析的装置，包括多色x射线源（11）; 用于安装样品以使其被x射线照射的安装装置（15）; 一个或多个荧光通道（17），其能够选择特定波长和能量的x射线，并具有用于检测所述选择的X射线的装置（20）; 衍射通道（28），其能够在由所述样品（14）的X射线衍射之后选择所述源极（11）处的特征X射线波长，并且具有用于检测所选择的特征x射线的装置（33）; 以及用于控制所述衍射通道（28）相对于所述样品（14）的弓形运动的致动装置（32），以便检测离开所述样品的不同衍射角的x射线。

6. 发明授权

US5376663A Macrocyclic compounds 失效
标题翻译：大环化合物
公开(公告)号：US5376663A
公开(公告)日：1994-12-27
申请号：US391538
申请日：1989-07-25
申请人： Martin E. Cooper , David K. Donald , David N. Hardern
发明人： Martin E. Cooper , David K. Donald , David N. Hardern
IPC分类号： C07D498/18 , C07D498/22 , C07H19/01 , A61K31/395 , A61K31/445 , C07D498/16
CPC分类号： C07D498/18 , C07D498/22 , C07H19/01
摘要： Compounds of formula (I), in which [R.sup.1 and R.sup.2 ], [R.sup.3 and R.sup.4 ] and [R.sup.5 and R.sup.6 ] represent a carbon-carbon bond or two hydrogen atoms; R.sup.2 additionally represents alkyl; R.sup.7, R.sup.8 and R.sup.9 represent groups including H or OH, R.sup.10 has various significances including alkyl and alkenyl; X and Y represent groups including O and (H, OH); R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.22 and R.sup.23 represent H or alkyl; R.sup.20 and R.sup.21 represent groups including O, (H, OH) and (H, O-alkyl), n is 1, 2 or 3, and in addition, Y, R.sup.10 and R.sup.23, together with the carbon atoms to which they are attached, may represent a heterocyclic ring, (with certain provisos) are described. Processes for making the compounds and pharmaceutical formulations containing them, e.g. for use as immunosuppressive agents, are also described. ##STR1##
摘要翻译： PCT No.PCT / GB88 / 01093 Sec。 371日期：1989年7月25日 102（e）日期1989年7月25日PCT提交1988年12月2日PCT公布。出版物WO89 / 05304 （I）化合物，其中[R 1和R 2]，[R 3和R 4]和[R 5和R 6]表示碳 - 碳键或两个氢原子; R2另外表示烷基; R7，R8和R9表示包括H或OH的基团，R10具有各种含义，包括烷基和烯基; X和Y表示包括O和（H，OH）的基团; R14，R15，R16，R17，R18，R19，R22和R23表示H或烷基; R 20和R 21表示包括O，（H，OH）和（H，O-烷基），n为1,2或3的基团，此外，Y，R 10和R 23与它们所连接的碳原子一起可以表示杂环（具有一定条件）。制备化合物和含有它们的药物制剂的方法，例如也用作免疫抑制剂。

7. 发明授权

US5352893A Isotopic-ratio plasma source mass spectrometer 失效
标题翻译：同位素比等离子体质谱仪
公开(公告)号：US5352893A
公开(公告)日：1994-10-04
申请号：US90205
申请日：1993-07-22
申请人： Philip A. Freedman
发明人： Philip A. Freedman
IPC分类号： H01J49/10 , H01J49/32
CPC分类号： H01J49/105 , H01J49/32
摘要： An isotopic-ratio mass spectrometer comprises an r.f. or microwave induced plasma ion source (1, 2, 3), an electrostatic ion-energy analyzer (75), a magnetic sector ion-momentum analyzer (82) wherein ions are dispersed at a first potential according to their mass-to-charge ratios, and two or more ion collectors (77) for receiving ions of different mass-to-charge ratios, wherein an apertured electrically conductive sampling member (19) is provided adjacent to the plasma (3) and communicates between the plasma and a first vacuum enclosure (23) evacuated by first pumping means (25); an apertured skimmer member (28) separates the first vacuum enclosure from a second vacuum enclosure (4) evacuated by second pumping means (5); an apertured differential pumping member (6) separates the second vacuum enclosure from a third vacuum enclosure (7) evacuated by third pumping means (43); an apertured analyzer entrance member (46) separates the third vacuum enclosure from a vacuum envelope (75, 76, 77) in which the electrostatic ion-energy analyzer ion-momentum analyzer, and ion detectors are disposed, the vacuum envelope being evacuated by fourth pumping means (131); and means (40) are provided for maintaining the sampling member at a second potential whereby ions generated in the plasma pass through each of the apertures and are accelerated to have a kinetic energy suitable for their mass analysis in the ion-momentum analyzer at said first potential.
摘要翻译： PCT No.PCT / GB92 / 00429 Sec。 371日期：1993年7月22日 102（e）日期1993年7月22日PCT 1991年3月11日PCT公布。公开号WO92 / 16008 日期：1992年9月17日。同位素比质谱仪包括r.f. 或微波感应等离子体离子源（1,2,3），静电离子能分析器（75），磁性扇形离子动量分析仪（82），其中根据其质量的电荷将离子分散在第一电位以及用于接收不同质荷比的离子的两个或更多个离子收集器（77），其中与等离子体（3）相邻地设置有孔导电取样构件（19），并且在等离子体和第一由第一泵送装置（25）抽真空的真空外壳（23）; 有孔分离器构件（28）将第一真空罩与由第二泵送装置（5）抽空的第二真空罩（4）分离; 有孔差分泵送构件（6）将第二真空罩与由第三泵送装置（43）排空的第三真空罩（7）分离; 有孔分析器入口构件（46）将第三真空容器与其中设置有静电离子能分析仪离子动量分析器和离子检测器的真空外壳（75,76,77）分离，真空外壳由第四泵送装置（131）; 并且提供装置（40）用于将采样构件保持在第二电位，由此在等离子体中产生的离子通过每个孔并被加速以具有适合于其在所述第一处的离子动量分析器中进行质量分析的动能潜在。

8. 发明授权

US5348978A Angiotensin converting enzyme inhibitors 失效
标题翻译：血管紧张素转换酶抑制剂
公开(公告)号：US5348978A
公开(公告)日：1994-09-20
申请号：US956877
申请日：1992-12-10
申请人： Andrew J. G. Baxter , Premji Meghani
发明人： Andrew J. G. Baxter , Premji Meghani
IPC分类号： A61K31/215 , A61K31/22 , A61P43/00 , C07C229/16 , C07C229/36 , C07C233/47 , C07C233/83 , C07C317/44 , C07C323/52 , C07C323/56 , C07D333/34 , C07D339/06 , C07F9/12 , C07F9/40 , A61K31/25 , A61K31/38 , C07C321/08
CPC分类号： C07D339/06 , C07C229/36 , C07C233/83 , C07C323/52 , C07C323/56 , C07D333/34 , C07F9/4075 , C07C2101/02 , C07C2101/08 , C07C2101/14 , C07C2103/74
摘要： Angiotensin converting enzyme inhibitors have the formula Z(CH.sub.2).sub.n CHR.sub.1 COOCHR.sub.2 COOHin which Z is --SR.sub.3, --COCHR.sub.4 NHCOR.sub.5, ##STR1## or --NHCHR.sub.7 COOH, R.sub.4, R.sub.5, R.sub.6, and R.sub.7, which may be the same or different, are each phenyl or alkylphenyl C.sub.7-12,R.sub.4 is hydrogen, alkyl C.sub.1-6, NHR.sub.8 or (CH.sub.2).sub.p R.sub.9,R.sub.2 is (CH.sub.2).sub.m XR.sub.10, alkyl C.sub.1-6 optionally substituted by a saturated 5- or 6-membered carbocyclic or heterocyclic ring, alkylhalo C.sub.1-6, alkylcyano C.sub.1-6, or alkyl phenyl C.sub.7-12, the phenyl being optionally substituted by NO.sub.2 or NH.sub.2,X is O, S(O).sub.q, C.dbd.O or NR.sub.11, andR.sub.10 is alkyl C.sub.1-6, alkylhalo C.sub.1-6, alkoxy C.sub.1-6, alkoxy C.sub.1-6 substituted by halogen, alkanoyl C.sub.1-6, S(O).sub.r R.sub.12, NR.sub.13 R.sub.14, phenyl, alkylphenyl C.sub.7-12, naphthalenyl or a 5-membered unsaturated heterocyclic ring,n is an integer from 0 to 6,m and p, which may be the same or different, are each an integer from 1 to 6,R.sub.9 is hydrogen, SR.sub.15 or phenyl optionally substituted by OR.sub.16,R.sub.3 and R.sub.15, which may be the same or different, are each hydrogen or alkanoyl C.sub.1-6,R.sub.8 is hydrogen or COOR.sub.17,q and r, which may be the same or different, are each 0, 1, or 2,R.sub.11, R.sub.13, R.sub.14, R.sub.16, and R.sub.17, which may be the same or different, are each hydrogen or alkyl C.sub.1-6, and R.sub.12 is hydrogen, alkyl C.sub.1-6 or phenyl.The compounds, and salts thereof, are useful as vasodilators.
摘要翻译： PCT No.PCT / GB91 / 00980 Sec。 371日期：1992年12月10日 102（e）日期1992年12月10日PCT Filed 1991年6月18日PCT公布。第WO92 / 00276号公报 1992年1月9日。血管紧张素转换酶抑制剂具有式Z（CH 2）n CHR 1 COOCHR 2 COOH，其中Z为-SR 3，-COCHR 4 NHCOR 5，或者-NHCHR 7 COOH，R 4，R 5，R 6和R 7，其可以相同或者不同的是苯基或烷基苯基C7-12，R4是氢，烷基C1-6，NHR8或（CH2）pR9，R2是（CH2）mXR10，任选地被饱和的5-或6-元烷基取代的C 1-6的烷基碳环或杂环，烷基卤C 1-6，烷基氰基C 1-6或烷基苯基C7-12，苯基任选被NO 2或NH 2取代，X是O，S（O）q，C = O或NR 11，R 10 是烷基C1-6，烷基卤代C1-6，烷氧基C1-6，被卤素取代的烷氧基C1-6，烷酰基C1-6，S（O）rR12，NR13R14，苯基，烷基苯基C7-12，萘基或5元环不饱和杂环，n为0-6的整数，m和p可相同或不同，分别为1至6的整数，R9为氢，SR15或任选被OR16取代的苯基，R3和R15，其可以相同或不同，各自为氢或烷酰基C 1-6，R 8为氢或COOR 17，q和r可以相同或不同，各自为0,1或2，R 11，R 13，R 14，R 16和R 17，其可以相同或不同的是氢或烷基C1-6，R12是氢，烷基C1-6或苯基。化合物及其盐可用作血管扩张剂。

9. 外观设计

USD348100S Medicament inhaler 失效
公开(公告)号：USD348100S
公开(公告)日：1994-06-21
申请号：US875426
申请日：1992-04-29
申请人： Rodger W. Clarke
设计人： Rodger W. Clarke

10. 发明授权

US5210227A Immunosuppressive compounds 失效
标题翻译：免疫抑制化合物
公开(公告)号：US5210227A
公开(公告)日：1993-05-11
申请号：US661802
申请日：1991-02-27
申请人： Hirokazu Tanaka , Martin E. Cooper , David K. Donald
发明人： Hirokazu Tanaka , Martin E. Cooper , David K. Donald
IPC分类号： A61K31/16 , A61K31/165 , A61K31/19 , A61K31/215 , A61K31/23 , A61P37/06 , C07C59/62 , C07C59/90 , C07C69/734 , C07C69/738 , C07C233/10 , C07C235/30 , C07C235/78 , C07D309/30 , C07D498/18
CPC分类号： C07D309/30 , C07C235/30 , C07C403/20 , C07C69/734 , C07C69/738 , C07C2101/14
摘要： Compounds of formula I, ##STR1## wherein R.sup.1 represents H, OH, protected OH or alkoxy; R.sup.2 represents H; R.sup.3 represents O or (H,OH); R.sup.4 represents methyl, ethyl, propyl or allyl; R.sup.5 represents OH, protected OH or alkoxy; R.sup.6 represents OH; R.sup.7 represents OH, alkoxy or NR.sup.8 R.sup.9 where R.sup.8 and R.sup.9 independently represent H, alkyl or aryl; in addition, R.sup.1 and R.sup.2 may together represent a second bond between the carbon atoms to which they are attached; and R.sup.6 and R.sup.7 may together represent O; and pharmaceutically acceptable salts thereof; are useful inter alia as immunosuppressive agents. The invention also provides the novel compounds of formula I.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式